FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808055426> ?p ?o ?g. }

• W2808055426 abstract "Objective: Assess the early onset of action of fremanezumab in the prevention of chronic migraine. Background: Migraine prevention, with earlier onset of action, could increase benefit to migraine patients. Fremanezumab is a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP). Design/Methods: 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing the efficacy, safety, and tolerability of 2 subcutaneous dose regimens of fremanezumab and placebo in adults with chronic migraine (CM). Patients were randomly assigned to 1 of 3 treatment groups: (1)monthly dosing: 675 mg fremanezumab followed by 225 mg fremanezumab at months 2 and 3, (2)quarterly dosing: 675 mg fremanezumab at month 1, followed by placebo injections at months 2 and 3, and (3)monthly administration of matching placebo. The primary efficacy endpoint, mean change from baseline to the 12-week treatment period in monthly average number of migraine days, was analyzed using an ANCOVA or the Wilcoxon rank sum test. Mean change from baseline to weeks 1–4, after 1 st dose was analyzed using a mixed-effect model for repeated measures. Results: Statistically significant reduction in number of monthly headache days of at least moderate severity was experienced during the 12-week period after 1st dose for both fremanezumab dosing regimens [monthly(−4.6 days);quarterly(−4.3 days); p Week 1, (−1.1 days; p Week 4, (−1.1 days; p=0.0006) versus placebo (−0.7 days) Posthoc analysis indicated more patients reported no headache of at least moderate severity [fremanezumab(69%; p=0.0036) versus placebo(61%)] by the next day following first injection. Conclusions: Onset of action with fremanezumab occurred rapidly for preventive treatment of migraine and significant improvement was maintained for both dosing regimens. Disclosure: Dr. Yeung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Aycardi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Bigal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Blankenbiller has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Grozinski-Wolff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Yang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Ma, MS has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva for employment. Dr. Brandes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Advisory boards: Amgen, Lilly, Promius, Supernus; consulting for Amgen, Promius. Dr. Brandes has received research support from Amgen, Teva, Allergan, Colucid, Zotrip." @default.
• W2808055426 created "2018-06-21" @default.
• W2808055426 creator A5018344799 @default.
• W2808055426 creator A5019830062 @default.
• W2808055426 creator A5041587271 @default.
• W2808055426 creator A5044997689 @default.
• W2808055426 creator A5054958208 @default.
• W2808055426 creator A5057078715 @default.
• W2808055426 creator A5060701773 @default.
• W2808055426 creator A5078169327 @default.
• W2808055426 date "2018-04-10" @default.
• W2808055426 modified "2023-09-23" @default.
• W2808055426 title "Early Onset of Action with Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (P4.102)" @default.
• W2808055426 hasPublicationYear "2018" @default.
• W2808055426 type Work @default.
• W2808055426 sameAs 2808055426 @default.
• W2808055426 citedByCount "0" @default.
• W2808055426 crossrefType "journal-article" @default.
• W2808055426 hasAuthorship W2808055426A5018344799 @default.
• W2808055426 hasAuthorship W2808055426A5019830062 @default.
• W2808055426 hasAuthorship W2808055426A5041587271 @default.
• W2808055426 hasAuthorship W2808055426A5044997689 @default.
• W2808055426 hasAuthorship W2808055426A5054958208 @default.
• W2808055426 hasAuthorship W2808055426A5057078715 @default.
• W2808055426 hasAuthorship W2808055426A5060701773 @default.
• W2808055426 hasAuthorship W2808055426A5078169327 @default.
• W2808055426 hasConcept C118303440 @default.
• W2808055426 hasConcept C126322002 @default.
• W2808055426 hasConcept C142724271 @default.
• W2808055426 hasConcept C163170386 @default.
• W2808055426 hasConcept C170493617 @default.
• W2808055426 hasConcept C197934379 @default.
• W2808055426 hasConcept C203092338 @default.
• W2808055426 hasConcept C204243189 @default.
• W2808055426 hasConcept C204787440 @default.
• W2808055426 hasConcept C27081682 @default.
• W2808055426 hasConcept C2777288759 @default.
• W2808055426 hasConcept C2778375690 @default.
• W2808055426 hasConcept C2778541695 @default.
• W2808055426 hasConcept C2910587157 @default.
• W2808055426 hasConcept C46821324 @default.
• W2808055426 hasConcept C535046627 @default.
• W2808055426 hasConcept C71924100 @default.
• W2808055426 hasConceptScore W2808055426C118303440 @default.
• W2808055426 hasConceptScore W2808055426C126322002 @default.
• W2808055426 hasConceptScore W2808055426C142724271 @default.
• W2808055426 hasConceptScore W2808055426C163170386 @default.
• W2808055426 hasConceptScore W2808055426C170493617 @default.
• W2808055426 hasConceptScore W2808055426C197934379 @default.
• W2808055426 hasConceptScore W2808055426C203092338 @default.
• W2808055426 hasConceptScore W2808055426C204243189 @default.
• W2808055426 hasConceptScore W2808055426C204787440 @default.
• W2808055426 hasConceptScore W2808055426C27081682 @default.
• W2808055426 hasConceptScore W2808055426C2777288759 @default.
• W2808055426 hasConceptScore W2808055426C2778375690 @default.
• W2808055426 hasConceptScore W2808055426C2778541695 @default.
• W2808055426 hasConceptScore W2808055426C2910587157 @default.
• W2808055426 hasConceptScore W2808055426C46821324 @default.
• W2808055426 hasConceptScore W2808055426C535046627 @default.
• W2808055426 hasConceptScore W2808055426C71924100 @default.
• W2808055426 hasOpenAccess W2808055426 @default.
• W2808055426 hasRelatedWork W2803952614 @default.
• W2808055426 hasRelatedWork W2805066472 @default.
• W2808055426 hasRelatedWork W2806435685 @default.
• W2808055426 hasRelatedWork W2806687972 @default.
• W2808055426 hasRelatedWork W2809523820 @default.
• W2808055426 hasRelatedWork W2809684180 @default.
• W2808055426 hasRelatedWork W2883358571 @default.
• W2808055426 hasRelatedWork W2885430857 @default.
• W2808055426 hasRelatedWork W2888596619 @default.
• W2808055426 hasRelatedWork W2898365980 @default.
• W2808055426 hasRelatedWork W2899506043 @default.
• W2808055426 hasRelatedWork W2910564004 @default.
• W2808055426 hasRelatedWork W2921858277 @default.
• W2808055426 hasRelatedWork W2976572331 @default.
• W2808055426 hasRelatedWork W3014490536 @default.
• W2808055426 hasRelatedWork W3015657679 @default.
• W2808055426 hasRelatedWork W3126954968 @default.
• W2808055426 hasRelatedWork W3159959646 @default.
• W2808055426 hasRelatedWork W3197018837 @default.
• W2808055426 hasRelatedWork W2809596465 @default.
• W2808055426 hasVolume "90" @default.
• W2808055426 isParatext "false" @default.
• W2808055426 isRetracted "false" @default.
• W2808055426 magId "2808055426" @default.
• W2808055426 workType "article" @default.